Brokers Issue Forecasts for CGTX FY2024 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities researchers at Brookline Capital Management issued their FY2024 earnings per share estimates for Cognition Therapeutics in a note issued to investors on Monday, January 27th. Brookline Capital Management analyst T. Bussian expects that the company will earn ($0.83) per share for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.86) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.

Other equities analysts also recently issued reports about the stock. HC Wainwright upped their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Chardan Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 19th. Finally, B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $8.30.

Cognition Therapeutics Trading Up 0.3 %

CGTX opened at $0.76 on Wednesday. The stock’s fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.69. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The stock has a market cap of $31.61 million, a PE ratio of -0.78 and a beta of 0.95.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Cognition Therapeutics during the fourth quarter worth approximately $26,000. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at $27,000. Sigma Planning Corp grew its holdings in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after purchasing an additional 24,050 shares during the period. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.